Long-term treatment for venous thromboembolism

Current Opinion in Hematology

Volumn 7, Issue 5, 2000, Pages 302-308

  Couturaud, Francis ^a   Kearon, Clive ^b  

^a SERVICE DE RHUMATOLOGIE   (France)

^b HENDERSON GENERAL HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; DALTEPARIN; ENOXAPARIN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN; WARFARIN;

ANTICOAGULATION; BLEEDING; CLINICAL TRIAL; DRUG EFFECT; DRUG EFFICACY; DRUG INDICATION; ENDARTERECTOMY; HUMAN; INTERNATIONAL STANDARD UNIT; PRIORITY JOURNAL; RECURRENT DISEASE; REVIEW; RISK FACTOR; THROMBOEMBOLISM; TREATMENT INDICATION; VEIN THROMBOSIS; VENA CAVA FILTER;

ANTICOAGULANTS; FOLLOW-UP STUDIES; HEMORRHAGE; HUMANS; RECURRENCE; RISK FACTORS; THROMBOEMBOLISM; VENOUS THROMBOSIS;

EID: 0033884065     PISSN: 10656251     EISSN: None     Source Type: Journal    
DOI: 10.1097/00062752-200009000-00008     Document Type: Review

References (54)

1. 1 Ginsberg JS: Management of venous thromboembolism. N Engl J Med 1996, 335:1816-28.
2. 2 Research Committee of The British Thoracic Society: Optimum duration of anticoagulation for deep-vein thrombosis and pulmonary embolism. Lancet 1992, 340:873-876.
3. 3 Levine MN, Hirsh J, Gent M, et al.: Optimal duration of oral anticoagulant therapy: a randomized trial comparing 4 weeks with three months of warfarin therapy in patients with proximal deep vein thrombosis. Thromb Haemost 1995, 74:606-611.
4. 4 Schulman S, Rhedin AS, Lindmarker P, et al., and the Duration of Anticoagulation Trial Study Group: A comparison of 6 weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism. N Engl J Med 1995, 332:1661-1665.
5. 5 Prandoni P, Lensing AWA, Büller HR, et al.: Deep-vein thrombosis and the incidence of subsequent symptomatic cancer. N Engl J Med 1992, 327:1128-33.
6. 6 Pini M, Aiello S, Manotti C, et al.: Low molecular weight heparin versus warfarin in the prevention of recurrences after deep vein thrombosis. Thromb Haemost 1994, 72:191-197.
7. 7 Kearon C, Gent M, Hirsh J, et al.: A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism. N Engl J Med 1999, 340:901-907.
8. 8 Kearon C, Crowther M, Hirsh J: Management of patients with hereditary hypercoagulable disorders. Ann Rev Med 2000, 51:169-185.
9. 9 Lane DA, Mannucci PM, Bauer KA, et al.: Inherited thrombophilia: part 1. Thromb Haemost 1996, 76:651-662.
10. 10 Lane DA, Mannucci PM, Bauer KA, et al.: Inherited thrombophilia: part 2. Thromb Haemost 1996, 76:824-834.
11. 11 Rosendaal FR: Venous thrombosis: a multicausal disease. Lancet 1999, 353:1167-1173.
12. 12 Schulman S, Svenungsson E, Granqvist S, and the Duration of Anticoagulation Study Group: Anticardiolipin antibodies predict early recurrence of thromboembolism and death among patients with venous thromboembolism following anticoagulant therapy. Am J Med 1998, 104:332-338.
13. 13 Cattaneo M: Hyperhomocysteinemia, atherosclerosis and thrombosis. Thromb Haemost 1999, 81:165-176.
14. 14 Eichinger S, Stümpflen A, Hirschl M, et al.: Hyperhomocysteinemia is a risk factor of recurrent venous thromboembolism. Thromb Haemost 1998, 80:566-569.
15. 15 Ridker PM, Miletich JP, Stampfer MJ, et al.: Factor V Leiden and risks of recurrent idiopathic venous thromboembolism. Circulation 1995, 92:2800-2802.
16. 506→Gln mutation in the gene factor V (factor V Leiden). N Engl J Med 1997, 336:399-403.
17. 17 Eichinger S, Pabinger I, Stümpflen A, et al.: The risk of recurrent venous thromboembolism in patients with and without factor V Leiden. Thromb Haemost 1997, 77:624-628.
18. 18 Lindmarker P, Schulman S, Sten-Linder M, et al., and the DURAC Trial Study Group. The risk of recurrent venous thromboembolism in carriers and non-carriers of the G1691A allele in the coagulation factor V gene and the G20210A allele in the prothrombin gene. Thromb Haemost 1999, 81:684-689.
19. 19 Poort SR, Rosendaal FR, Reitsma PH, et al.: A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 1996, 88:3698-3703.
20. 20 Eichinger S, Minar E, Hirschl M, et al.: The risk of early recurrent venous thromboembolism after oral anticoagulant therapy in patients with the G20210A transition in the prothrombin gene. Thromb Haemost 1999, 81:14-17.
21. 21 Margaglione M, D'Andrea G, Colaizzo D, et al.: Coexistence of factor V Leiden and factor II A20210 mutations and recurrent venous thromboembolism. Thromb Haemost 1999, 82:1583-1587.
22. 22 De Stephane, Martenelli I, Mannucci PM, et al.: The risk of recurrent deep venous thrombosis among heterozygous carriers of both factor V Leiden and the G20210A prothrombin mutation. N Engl J Med 1999, 341:801-806.
23. 23 Prandoni P, Lensing AWA, Cogo A, et al.: The long-term clinical course of acute deep venous thrombosis. Ann Intern Med 1996, 125:1-7.
24. 24 van den Belt AGM, Sanson BJ, Simioni P, et al.: Recurrence of venous thromboembolism in patients with familial thrombophilia. Arch Intern Med 1997, 157:2227-2232.
25. 25 Rosendall FR: High levels of factor VIII and venous thrombosis. Thromb Haemost 2000, 83:1-2.
26. 26 Meijers JCM, Tekelenburg WLH, Bouma BN, et al.: High levels of coagulation factor XI as a risk factor for venous thrombosis. N Engl J Med 2000, 342:696-701.
27. 27 Kraaijenhagen RA, in't Anker PS, Koopman MMW, et al.: High plasma concentration of factor VIIIc is a major risk factor for venous thromboembolism. Thromb Haemost 2000, 83:5-9.
28. 28 Eichinger S, Minar E, Hirschl M, et al.: The risk of early recurrent venous thromboembolism (VTE) in patients with increased factor VIII:c (FVIII) and a first episode of spontaneous VTE. Thromb Haemost 1999, 82(suppl):5-6.
29. 29 The Columbus Investigators: Low molecular weight heparin in the treatment of patients with venous thromboembolism. N Engl J Med 1997, 337:657-662.
30. 30 Hulley S, Grady D, Bush T, et al., for the Heart and estrogen/progestin Replacement Study (HERS) Research Group: Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA 1998, 280:605-613.
31. 31 White RH, Zhou H, Romano PS: Incidence of idiopathic deep venous thrombosis and secondary thromboembolism among ethnic groups in California. Ann Intern Med 1998, 128:737-740.
32. 32 Schulman S, Granqvist S, Holmström M, et al., and the Duration of Anticoagulation Trial Study Group. The duration of oral anticoagulant therapy after a second episode of venous thromboembolism. N Engl J Med 1997, 336:393-398.
33. 33 Schulman S, Lindmarker P, for the Duration of Anticoagulation Trial: Incidence of cancer after prophylaxis with warfarin against recurrent venous thromboembolism. N Engl J Med 2000, 342:1953-1958.
34. 34 Landefeld CS, Beyth RJ: Anticoagulant-related bleeding: clinical epidemiology, prediction, and prevention. Am J Med 1993, 95:315-328.
35. 35 Palareti G, Leali N, Coccheri S, et al., on behalf of the Italian Study on Complications of Oral Anticoagulant Therapy: Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT). Lancet 1996, 348:423-428.
36. 36 White RH, Beyth RJ, Zhou H, et al.: Major bleeding after hospitalization for deep-venous thrombosis. Am J Med 1999, 107:414-424.
37. 37 Beyth RJ, Quinn LM, Landefeld CS: Prospective evaluation of an index for predicting the risk of major bleeding in outpatients treated with warfarin. Am J Med 1998, 105:91-99.
38. 38 Kuijer PMM, Hutten BA, Prins MH, et al.: Prediction of the risk of bleeding during anticoagulant treatment for venous thromboembolism. Arch Intern Med 1999, 159:457-460.
39. 39 Poller L, Shiach CR, MacCallum PK, et al., on behalf of the European Concerted Action on Anticoagulation: Multicentre randomised study of computerised anticoagulant dosage. Lancet 1998, 352:1505-1509.
40. 40 Aithal GP, Day CP, Kesteven PJL, et al.: Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet 1999, 353:717-719.
41. 41 Douketis JD, Kearon C, Bates S, et al.: Risk of fatal pulmonary embolism in patients with treated venous thromboembolism. JAMA 1998, 279:458-462.
42. 42 Hull R, Delmore T, Genton E, et al.: Warfarin sodium versus low-dose heparin in the long-term treatment of venous thrombosis. N Engl J Med 1979, 301:855-858.
43. 43 Bynum LJ, Wilson JE: Low-dose heparin therapy in the long-term management of venous thromboembolism. Am J Med 1979, 61:553-556.
44. 44 Hull R, Delmore T, Carter C, et al.: Adjusted subcutaneous heparin versus warfarin sodium in the long-term treatment of venous thrombosis. N Engl J Med 1982, 306:189-194.
45. 45 Monreal M, Lafoz E, Olive A, et al.: Comparison of subcutaneous unfractionated heparin with a low molecular weight heparin (Fragmin) in patients with venous thromboembolism and contraindication to Coumarin. Thromb Haemost 1994, 71:7-11.
46. 46 Pini M, Aiello S, Manotti C, et al: Low molecular weight heparin versus warfarin in the prevention of recurrences after deep vein thrombosis. Thromb Haemost 1994, 72:191-197.
47. 47 Das SK, Cohen AT, Edmondson RA, et al.: Low-molecular-weight heparin versus warfarin for prevention of recurrent venous thromboembolism. World J Surg 1996, 20:521-527.
48. 48 Lopaciuk S, Bielska-Falda H, Noszczyk W, et al.: Low molecular weight heparin versus acenocoumarol in the secondary prophylaxis of deep vein thrombosis. Thromb Haemost 1999, 81:26-31.
49. 48 Gonzalez-Fajardo JA, Arreba E, Castrodeza J, et al.: Venographic comparison of subcutaneous low-molecular-weight heparin with oral anticoagulant therapy in the long-term treatment of deep venous thrombosis. J Vasc Surg 1999, 30:283-292.
50. 50 Hirsh J, Weitz JI: New antithrombotic agents. Lancet 1999, 353:1431-1436.
51. 51 Decousus H, Leizorovicz A, Parent F, et al., for the Prévention du Risque d'Embolie Pulmonaire par Interruption Cave Study Group: A clinical trial of vena caval filters in the prevention of pulmonary embolism in patients with proximal deep-vein thrombosis. N Engl J Med 1998, 338:409-415.
52. 52 Hyers TM, Agnelli G, Hull RD, et al.: Antithrombotic therapy for venous thromboembolic disease. Chest 1998, 114(suppl):561-578.
53. 53 Moser KM, Auger WR, Fedullo PF, et al.: Chronic thromboembolic pulmonary hypertension : clinical picture and surgical treatment. Eur Respir J 1992, 5:334-42.
54. 54 Brandjes DP, Büller HR, Heijboer H, et al.: Randomised trial of effect of compression stockings in patients with symptomatic proximal-vein thrombosis. Lancet 1997; 349:759-62.